Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TCR2 THERAPEUTICS INC.

(TCRR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & Immunotherapy

10/05/2021 | 09:00am EST

TCR2Therapeutics Inc. announced the e-poster presentation of new preclinical data at the American Association for Cancer Research (AACR) Virtual Special Conference on Tumor Immunology and Immunotherapy, taking place October 5-6, 2021. The e-poster titled “Expression of an IL-15 Receptor Fusion Protein Enhances the Persistence of TRuC-T Cells” highlights preclinical data on the Company’s proprietary mesothelin-directed T Cell Receptor Fusion Construct (TRuC®) T cells that express IL-15-based enhancements as a strategy for improving T cell persistence. The co-expression of these IL-15 enhancements enriched for naïve and central memory T cells, upregulated the stemness-associated transcription factor TCF-1 and increased TRuC-T cell proliferation upon repeated stimulation with mesothelin-expressing cancer cell lines. In addition, IL-15 promoted the survival of TRuC-T cells in the absence of T cell receptor (TCR) or exogenous cytokine stimulation. In a mesothelioma xenograft mouse model, IL-15 co-expression resulted in a higher number of TRuC-T cells in the tumor and significantly increased their persistence in peripheral blood. The administration of a single dose of IL-15 enhanced TRuC-T cells cleared tumors in all mice and fully protected them from tumor rechallenge.


© S&P Capital IQ 2021
All news about TCR2 THERAPEUTICS INC.
11/22TCR2 Therapeutics Inc. Announces Resignation of Mayur Somaiya, Effective December 10, 2..
CI
11/11Tcr-2 therapeutics reports third quarter 2021 financial results and provides corporate ..
AQ
11/10TCR2 THERAPEUTICS INC. Management's Discussion and Analysis of Financial Condition and..
AQ
11/10TCR2 Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate U..
PU
11/10TCR² Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate U..
AQ
11/10TCR2 Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months E..
CI
11/01TCR2 Therapeutics Announces Expansion of U.S. Manufacturing Capacity - Form 8-K
PU
11/01TCR2 THERAPEUTICS INC. : Costs Associated with Exit or Disposal Activities, Financial Stat..
AQ
11/01TCR² Therapeutics Announces Expansion of U.S. Manufacturing Capacity
AQ
11/01Tcr2 Therapeutics Inc. Announces Expansion of U.S. Manufacturing Capacity
CI
More news
Analyst Recommendations on TCR2 THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -100,0 M - -
Net cash 2021 246 M - -
P/E ratio 2021 -1,89x
Yield 2021 -
Capitalization 191 M 191 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 164
Free-Float 96,4%
Chart TCR2 THERAPEUTICS INC.
Duration : Period :
TCR2 Therapeutics Inc. Technical Analysis Chart | TCRR | US87808K1060 | MarketScreener
Technical analysis trends TCR2 THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 5,01 $
Average target price 24,90 $
Spread / Average Target 397%
EPS Revisions
Managers and Directors
Garry E. Menzel President, Chief Executive Officer & Director
Mayur Ian Somaiya Chief Financial Officer
Ansbert K. Gadicke Chairman
Robert Hofmeister Chief Scientific Officer
Alfonso Quintás-Cardama Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
TCR2 THERAPEUTICS INC.-83.80%191
MODERNA, INC.193.60%124 359
LONZA GROUP AG25.98%58 058
IQVIA HOLDINGS INC.46.05%49 991
SEAGEN INC.-13.93%27 564
CELLTRION, INC.-41.36%24 298